{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:09:43Z","timestamp":1790885383141,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Science and Technology Program","award":["2022KY1110"],"award-info":[{"award-number":["2022KY1110"]}]},{"name":"\u201cXinyu\u201d Talent Program of the First Affiliated Hospital of Ningbo University","award":["XYJH-1-WJQ"],"award-info":[{"award-number":["XYJH-1-WJQ"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14112-0","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:55:56Z","timestamp":1744646156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a clinical-molecular prediction model for central lymph node metastasis in cN0 stage papillary thyroid microcarcinoma: a retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jinqiu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingze","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"3","key":"14112_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"14112_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","volume":"8","author":"M Li","year":"2020","unstructured":"Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468\u201370.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"14112_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"UC Megwalu","year":"2022","unstructured":"Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the united States: 2000\u20132018. Thyroid. 2022;32(5):560\u201370.","journal-title":"Thyroid"},{"issue":"6","key":"14112_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1210\/clinem\/dgac739","volume":"108","author":"JS Lee","year":"2023","unstructured":"Lee JS, et al. Aggressive subtypes of papillary thyroid carcinoma smaller than 1\u00a0cm. J Clin Endocrinol Metab. 2023;108(6):1370\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"14112_CR5","doi-asserted-by":"crossref","unstructured":"Parvathareddy SK et al. Risk factors for cervical lymph node metastasis in middle Eastern papillary thyroid microcarcinoma. J Clin Med. 2022;11(15).","DOI":"10.3390\/jcm11154613"},{"key":"14112_CR6","doi-asserted-by":"publisher","first-page":"107327482210849","DOI":"10.1177\/10732748221084926","volume":"29","author":"Y Shi","year":"2022","unstructured":"Shi Y, et al. Clinicopathological findings associated with cervical lymph node metastasis in papillary thyroid microcarcinoma: A retrospective study in China. Cancer Control. 2022;29:10732748221084926.","journal-title":"Cancer Control"},{"issue":"4","key":"14112_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5455\/medarh.2016.70.314-317","volume":"70","author":"R Miftari","year":"2016","unstructured":"Miftari R, et al. Management of the patient with aggressive and resistant papillary thyroid carcinoma. Med Arch. 2016;70(4):314\u20137.","journal-title":"Med Arch"},{"issue":"1","key":"14112_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-00997-6","volume":"23","author":"P Asimakopoulos","year":"2020","unstructured":"Asimakopoulos P, et al. Management of the neck in Well-Differentiated thyroid cancer. Curr Oncol Rep. 2020;23(1):1.","journal-title":"Curr Oncol Rep"},{"key":"14112_CR9","doi-asserted-by":"publisher","first-page":"109103","DOI":"10.1016\/j.ejrad.2020.109103","volume":"129","author":"Z Xing","year":"2020","unstructured":"Xing Z, et al. Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis. Eur J Radiol. 2020;129:109103.","journal-title":"Eur J Radiol"},{"issue":"12","key":"14112_CR10","first-page":"1343","volume":"42","author":"Administration NHCotPsRoCMAaH","year":"2022","unstructured":"Administration NHCotPsRoCMAaH. Guidelines for the diagnosis and treatment of thyroid carcinoma (2022 version). Chin J Practical Surg. 2022;42(12):1343\u201363.","journal-title":"Chin J Practical Surg"},{"issue":"6","key":"14112_CR11","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/lary.29912","volume":"132","author":"KM Alsubaie","year":"2022","unstructured":"Alsubaie KM, et al. Prophylactic central neck dissection for clinically Node-Negative papillary thyroid carcinoma. Laryngoscope. 2022;132(6):1320\u20138.","journal-title":"Laryngoscope"},{"issue":"1","key":"14112_CR12","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1038\/s41467-020-18497-3","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu J, et al. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics. Nat Commun. 2020;11(1):4807.","journal-title":"Nat Commun"},{"issue":"8","key":"14112_CR13","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1016\/j.acra.2024.03.012","volume":"31","author":"S Zhang","year":"2024","unstructured":"Zhang S, et al. Ultrasound-Base radiomics for discerning lymph node metastasis in thyroid cancer: A systematic review and Meta-analysis. Acad Radiol. 2024;31(8):3118\u201330.","journal-title":"Acad Radiol"},{"issue":"6","key":"14112_CR14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40618-023-02262-6","volume":"47","author":"DN Lu","year":"2024","unstructured":"Lu DN, et al. Single-cell and bulk RNA sequencing reveal heterogeneity and diagnostic markers in papillary thyroid carcinoma lymph-node metastasis. J Endocrinol Invest. 2024;47(6):1513\u201330.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"14112_CR15","doi-asserted-by":"publisher","first-page":"e70172","DOI":"10.1002\/ctm2.70172","volume":"15","author":"G Xiao","year":"2025","unstructured":"Xiao G, et al. Single-cell RNA-sequencing and Spatial transcriptomic analysis reveal a distinct population of APOE(-) cells yielding pathological lymph node metastasis in papillary thyroid cancer. Clin Transl Med. 2025;15(1):e70172.","journal-title":"Clin Transl Med"},{"issue":"1","key":"14112_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40644-024-00719-2","volume":"24","author":"R Zhang","year":"2024","unstructured":"Zhang R, et al. Targeted sequencing of DNA\/RNA combined with radiomics predicts lymph node metastasis of papillary thyroid carcinoma. Cancer Imaging. 2024;24(1):75.","journal-title":"Cancer Imaging"},{"key":"14112_CR17","doi-asserted-by":"publisher","first-page":"107327482412953","DOI":"10.1177\/10732748241295347","volume":"31","author":"H Chen","year":"2024","unstructured":"Chen H, et al. Prediction model of cervical lymph node metastasis in papillary thyroid carcinoma. Cancer Control. 2024;31:10732748241295347.","journal-title":"Cancer Control"},{"key":"14112_CR18","doi-asserted-by":"publisher","first-page":"1034047","DOI":"10.3389\/fonc.2023.1034047","volume":"13","author":"F Zhao","year":"2023","unstructured":"Zhao F, et al. A LASSO-based model to predict central lymph node metastasis in preoperative patients with cN0 papillary thyroid cancer. Front Oncol. 2023;13:1034047.","journal-title":"Front Oncol"},{"key":"14112_CR19","doi-asserted-by":"publisher","first-page":"1001954","DOI":"10.3389\/fcell.2022.1001954","volume":"10","author":"K Wang","year":"2022","unstructured":"Wang K, et al. Potential diagnostic of lymph node metastasis and prognostic values of TM4SFs in papillary thyroid carcinoma patients. Front Cell Dev Biol. 2022;10:1001954.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"14112_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13046-016-0447-3","volume":"35","author":"QX Wang","year":"2016","unstructured":"Wang QX, et al. A panel of four genes accurately differentiates benign from malignant thyroid nodules. J Exp Clin Cancer Res. 2016;35(1):169.","journal-title":"J Exp Clin Cancer Res"},{"key":"14112_CR21","doi-asserted-by":"publisher","first-page":"e16952","DOI":"10.7717\/peerj.16952","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Predicting central cervical lymph node metastasis in papillary thyroid microcarcinoma using deep learning. PeerJ. 2024;12:e16952.","journal-title":"PeerJ"},{"issue":"12","key":"14112_CR22","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.21037\/gs-23-456","volume":"12","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, et al. Prediction of central lymph node metastasis in patients with papillary thyroid microcarcinoma by gradient-boosting decision tree model based on ultrasound radiomics and clinical features. Gland Surg. 2023;12(12):1722\u201334.","journal-title":"Gland Surg"},{"issue":"2","key":"14112_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10238-020-00675-8","volume":"21","author":"ZY Rui","year":"2021","unstructured":"Rui ZY, et al. A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis. Clin Exp Med. 2021;21(2):277\u201386.","journal-title":"Clin Exp Med"},{"key":"14112_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2147\/OTT.S191700","volume":"12","author":"N Li","year":"2019","unstructured":"Li N, et al. Correlations of LncRNAs with cervical lymph node metastasis and prognosis of papillary thyroid carcinoma. Onco Targets Ther. 2019;12:1269\u201378.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"14112_CR25","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1093\/oncolo\/oyae086","volume":"29","author":"L Hu","year":"2024","unstructured":"Hu L, et al. Enhanced stiffness in peri-cancerous tissue: a marker of poor prognosis in papillary thyroid carcinoma with lymph node metastasis. Oncologist. 2024;29(9):e1132\u201348.","journal-title":"Oncologist"},{"issue":"4","key":"14112_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.30699\/ijp.2023.2005196.3134","volume":"18","author":"S Didehban","year":"2023","unstructured":"Didehban S, Abdollahi A, Meysamie A. Evaluation of etiology, clinical manifestations, diagnosis, Follow-up, histopathology and prognosis factors in papillary thyroid microcarcinoma: A systematic review and Meta-analysis. Iran J Pathol. 2023;18(4):380\u201391.","journal-title":"Iran J Pathol"},{"issue":"9","key":"14112_CR27","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00268-021-06185-2","volume":"45","author":"R Nagaoka","year":"2021","unstructured":"Nagaoka R, et al. Multifocality and progression of papillary thyroid microcarcinoma during active surveillance. World J Surg. 2021;45(9):2769\u201376.","journal-title":"World J Surg"},{"issue":"1","key":"14112_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/sjmms.sjmms_393_21","volume":"10","author":"AA Malik","year":"2022","unstructured":"Malik AA, et al. Characteristics and management of papillary thyroid microcarcinoma in the united Arab Emirates: experience from a large tertiary hospital. Saudi J Med Med Sci. 2022;10(1):42\u20138.","journal-title":"Saudi J Med Med Sci"},{"issue":"1","key":"14112_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12902-023-01521-0","volume":"23","author":"H Huang","year":"2023","unstructured":"Huang H, et al. A prediction model for identifying high-risk lymph node metastasis in clinical low-risk papillary thyroid microcarcinoma. BMC Endocr Disord. 2023;23(1):260.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"14112_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12902-022-01186-1","volume":"22","author":"Y Huang","year":"2022","unstructured":"Huang Y, et al. Exploring risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: construction of a novel population-based predictive model. BMC Endocr Disord. 2022;22(1):269.","journal-title":"BMC Endocr Disord"},{"issue":"45","key":"14112_CR31","doi-asserted-by":"publisher","first-page":"30911","DOI":"10.1021\/acsnano.4c07969","volume":"18","author":"H Tang","year":"2024","unstructured":"Tang H, et al. The emerging era of molecular medicine. ACS Nano. 2024;18(45):30911\u20138.","journal-title":"ACS Nano"},{"key":"14112_CR32","doi-asserted-by":"publisher","first-page":"991906","DOI":"10.3389\/fendo.2022.991906","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, et al. Screening and validation of lymph node metastasis risk-factor genes in papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2022;13:991906.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"14112_CR33","doi-asserted-by":"crossref","unstructured":"Kilicarslan S, Hiz-Cicekliyurt MM. Identification of potential biomarkers of papillary thyroid carcinoma. Endocrine 2024.","DOI":"10.1007\/s12020-024-04068-9"},{"key":"14112_CR34","doi-asserted-by":"publisher","first-page":"110792","DOI":"10.1016\/j.cellsig.2023.110792","volume":"109","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, et al. MicroRNA-142-3P suppresses the progression of papillary thyroid carcinoma by targeting FN1 and inactivating FAK\/ERK\/PI3K signaling. Cell Signal. 2023;109:110792.","journal-title":"Cell Signal"},{"key":"14112_CR35","doi-asserted-by":"crossref","unstructured":"Zhang S et al. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods. Biosci Rep. 2019;39(4).","DOI":"10.1042\/BSR20190083"},{"key":"14112_CR36","doi-asserted-by":"publisher","first-page":"610547","DOI":"10.3389\/fonc.2021.610547","volume":"11","author":"W Sun","year":"2021","unstructured":"Sun W, et al. The NEAT1_2\/miR-491 axis modulates papillary thyroid cancer invasion and metastasis through TGM2\/NF\u03bab\/FN1 signaling. Front Oncol. 2021;11:610547.","journal-title":"Front Oncol"},{"issue":"1","key":"14112_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/0109298665308502240820115618","volume":"30","author":"C Chen","year":"2023","unstructured":"Chen C, Shen Z. FN1 promotes thyroid carcinoma cell proliferation and metastasis by activating the NF-\u039ab pathway. Protein Pept Lett. 2023;30(1):54\u201364.","journal-title":"Protein Pept Lett"},{"issue":"1","key":"14112_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-018-0645-x","volume":"11","author":"M Si","year":"2018","unstructured":"Si M, Lang J. The roles of Metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11(1):107.","journal-title":"J Hematol Oncol"},{"issue":"0","key":"14112_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5604\/01.3001.0010.3794","volume":"71","author":"A Bizo\u0144","year":"2017","unstructured":"Bizo\u0144 A, J\u0119dryczko K, Milnerowicz H. The role of Metallothionein in oncogenesis and cancer treatment. Postepy Hig Med Dosw (Online). 2017;71(0):98\u2013109.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"9","key":"14112_CR40","first-page":"5179","volume":"37","author":"B Wojtczak","year":"2017","unstructured":"Wojtczak B, et al. Metallothionein isoform expression in benign and malignant thyroid lesions. Anticancer Res. 2017;37(9):5179\u201385.","journal-title":"Anticancer Res"},{"issue":"3","key":"14112_CR41","first-page":"1760","volume":"11","author":"Y Chen","year":"2019","unstructured":"Chen Y, et al. Low Metallothionein 1\u00a0M (MT1M) is associated with thyroid cancer cell lines progression. Am J Transl Res. 2019;11(3):1760\u201370.","journal-title":"Am J Transl Res"},{"key":"14112_CR42","doi-asserted-by":"crossref","unstructured":"Laskou A et al. Different forms of TFF3 in the human endocervix, including a complex with IgG Fc binding protein (FCGBP), and further aspects of the Cervico-Vaginal innate immune barrier. Int J Mol Sci 2024;25(4).","DOI":"10.3390\/ijms25042287"},{"key":"14112_CR43","doi-asserted-by":"crossref","unstructured":"Lukyanov SA et al. Prediction of the aggressive clinical course of papillary thyroid carcinoma based on fine needle aspiration biopsy molecular testing. Int J Mol Sci 2024;25(13).","DOI":"10.3390\/ijms25137090"},{"issue":"1","key":"14112_CR44","doi-asserted-by":"publisher","first-page":"11005","DOI":"10.1038\/s41598-024-61839-0","volume":"14","author":"SH Ju","year":"2024","unstructured":"Ju SH, et al. Transcriptomic characteristics according to tumor size and SUV(max) in papillary thyroid cancer patients. Sci Rep. 2024;14(1):11005.","journal-title":"Sci Rep"},{"key":"14112_CR45","doi-asserted-by":"publisher","first-page":"2130229","DOI":"10.1155\/2021\/2130229","volume":"2021","author":"Y Xin","year":"2021","unstructured":"Xin Y, et al. Trefoil factor 3 inhibits thyroid cancer cell progression related to IL-6\/JAK\/STAT3 signaling pathway. Evid Based Complement Alternat Med. 2021;2021:2130229.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14112_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fendo.2020.00265","volume":"11","author":"J Mao","year":"2020","unstructured":"Mao J, et al. Risk factors for lymph node metastasis in papillary thyroid carcinoma: A systematic review and Meta-Analysis. Front Endocrinol (Lausanne). 2020;11:265.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"14112_CR47","doi-asserted-by":"publisher","first-page":"789310","DOI":"10.3389\/fendo.2021.789310","volume":"12","author":"X Gao","year":"2021","unstructured":"Gao X, et al. Predictors and a prediction model for central cervical lymph node metastasis in papillary thyroid carcinoma (cN0). Front Endocrinol (Lausanne). 2021;12:789310.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"14112_CR48","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.acra.2022.09.002","volume":"30","author":"Y Peng","year":"2023","unstructured":"Peng Y, et al. Prediction of central lymph node metastasis in cN0 papillary thyroid carcinoma by CT radiomics. Acad Radiol. 2023;30(7):1400\u20137.","journal-title":"Acad Radiol"},{"key":"14112_CR49","doi-asserted-by":"publisher","first-page":"1075598","DOI":"10.3389\/fendo.2023.1075598","volume":"14","author":"T Ma","year":"2023","unstructured":"Ma T, et al. A clinical and molecular pathology prediction model for central lymph node metastasis in cN0 papillary thyroid microcarcinoma. Front Endocrinol (Lausanne). 2023;14:1075598.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"14112_CR50","first-page":"139","volume":"29","author":"D Zhu","year":"2023","unstructured":"Zhu D, et al. Predictive value of ultrasound imaging characteristics and a BRAF V600E nomogram for central lymph node metastasis risk in papillary thyroid microcarcinoma. Altern Ther Health Med. 2023;29(8):139\u201343.","journal-title":"Altern Ther Health Med"},{"key":"14112_CR51","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2147\/CMAR.S159583","volume":"10","author":"H Ren","year":"2018","unstructured":"Ren H, et al. Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res. 2018;10:1005\u201313.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"14112_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12885-024-12004-3","volume":"24","author":"P Qiu","year":"2024","unstructured":"Qiu P, et al. Development of a nomogram for prediction of central lymph node metastasis of papillary thyroid microcarcinoma. BMC Cancer. 2024;24(1):235.","journal-title":"BMC Cancer"},{"key":"14112_CR53","doi-asserted-by":"crossref","unstructured":"Titov SE et al. Could SLC26A7 be a promising marker for preoperative diagnosis of High-Grade papillary thyroid carcinoma?? Diagnostics (Basel). 2024;14(23).","DOI":"10.3390\/diagnostics14232652"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14112-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:02:33Z","timestamp":1744650153000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14112-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14112"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14112-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"25 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Ningbo University (Approval No. 2021-R140). All TCGA data used in this study are publicly available through the National Cancer Institute\u2019s Genomic Data Commons portal (\n                      \n                      ). Written informed consent was obtained from all participants involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"693"}}